Melanoma: From Impossible to Treat to Poster Child for Targeted TherapiesByNicole BeaginOctober 23rd 2013An AJMC Panel Discussion
Status in the States: In Louisiana, Will Privatization Affect Efforts to Stop Cancer?ByMary K. CaffreyOctober 23rd 2013
Dual HER2 Blockade Less Effective in PI3KCA-Mutant Breast CancerBySandra HannerOctober 23rd 2013European Cancer Congress 2013
Trebananib Shows Promise in Recurrent Platinum-Sensitive Ovarian CancerByBonnie GillisOctober 23rd 2013European Cancer Congress 2013
Pooled Analysis Reinforces Long-Term Survival Benefit With IpilimumabByAndrew J. RothOctober 23rd 2013European Cancer Congress 2013
New Approaches to Medicaid Expansion: Hybrid Plans Offer Alternatives for Covering More PeopleByStanton R. Mehr,Mary K. CaffreyOctober 22nd 2013
In Historic Vote, FDA Backs Perjeta for Pre-surgical Breast Cancer TreatmentByBen LeachOctober 22nd 2013
Ofatumumab Receives Breakthrough Therapy Designation for Earlier Use in CLLByBen LeachOctober 22nd 2013